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Aims
To observe the safety and effectiveness of recombinant
human growth hormone (rhGH) replacement therapy
(GHRT) in postoperative craniopharyngioma (CP)
children.
Subjects and methods
We reviewed the records for all patients undergoing
GHRT at our hospital over the study period. Patients
were included if they had received CP resection, GHRT
for at least 12 months, and records of serial magnetic
resonance imaging data and data for treatment, pituitary
hormone profiles and growth chart were available. GH-
naïve control patients were selected from our hospital
database of patients carried out the same surgery.
Patients were matched for date of surgery, age, site of
primary diagnosis and sex.
Results
18 patients were recruited with growth hormone defi-
ciency. In treatment group, all patients all gained accel-
eration in growth velocity and elevated growth factors
level. There were no recurrent tumors found in both
groups.
Conclusions
Our study demonstrates no increased risk for recurrent
in patients receiving GHRT, thus supporting a high
safety profile of GHRT in postoperative craniopharyn-
gioma children. Additionally, GHRT can provide a
significantly change in growth velocity compared with
control group.
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